NCT06924359

Brief Summary

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started Mar 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress46%
Mar 2025Aug 2027

Study Start

First participant enrolled

March 19, 2025

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

April 6, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 11, 2025

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Last Updated

April 11, 2025

Status Verified

April 1, 2025

Enrollment Period

2.5 years

First QC Date

April 6, 2025

Last Update Submit

April 6, 2025

Conditions

Alzheimer's Disease (AD)

Outcome Measures

Primary Outcomes (1)

  • Differences in Multimodal Ophthalmic Imaging parameter values among groups

    Baseline

Secondary Outcomes (1)

  • Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups

    Baseline

Study Arms (1)

Different stages of Alzheimer's disease

Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker

Interventions

Multimodal Ophthalmic Imaging and plasma biomarkerDIAGNOSTIC_TEST

Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.

Different stages of Alzheimer's disease

Eligibility Criteria

Age50 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

AD, MCI, SCD and CN

You may qualify if:

  • Male or female participants aged ≥ 50 years;
  • Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
  • Signed informed consent form

You may not qualify if:

  • Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
  • Inability to cooperate with cognitive assessments;
  • Refusal to undergo blood sampling.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University First Hospital

Beijing, China

RECRUITING

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2025

First Posted

April 11, 2025

Study Start

March 19, 2025

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2027

Last Updated

April 11, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)